Discovering
Tomorrow’s
Treatments Today
The Ivy Brain Tumor Center is a nonprofit translational research program that offers state-of-the-art clinical trials for patients with even the most aggressive brain tumors.
Brain Tumor Treatment at Ivy
The Ivy Brain Tumor Center is a leader in brain tumor research and treatment. The Ivy Center is located in Phoenix, Arizona, at Barrow Neurological Institute, the highest-volume operative brain tumor center in the U.S.
Whether benign or malignant, a brain tumor can be life-changing. The Ivy Center’s multidisciplinary team of healthcare professionals and scientists work to understand the molecular structure of each patient’s brain tumor to determine its pathology and the most effective treatment plan. Explore a variety of brain tumor types we treat.
Tumors we treat
As one of the world’s largest brain tumor treatment centers, the Ivy Center utilizes advanced therapies, state-of-the-art technology and innovative clinical trials to tailor each patient’s treatment plan to their individualized needs and circumstances. No two brain tumors are alike and each tumor requires a treatment regimen designed for its unique genetic composition.
While each patient’s brain tumor experience is different, those on the receiving end of the diagnosis share the overwhelming feelings of worry, fear and stress. No one should have to cope with a brain cancer diagnosis alone. We understand the uncertainty of your circumstances. Our team is here for you every step of the way.
Clinical Trials
Ivy Brain Tumor Center clinical trials play a pivotal role in developing new therapies and advancing treatment options that make a significant impact on patient outcomes. The Ivy Center operates the world’s largest Phase 0 clinical trials program in the world.
What are Phase 0 Clinical Trials?
Clinical trials test new drugs, equipment and treatments that have not yet been approved. Phase 0 clinical trials study whether new drugs reach the intended brain tumor target and have the desired effect. This allows us to quickly advance drugs that show promise while eliminating those that do not.
What to Expect
Based on a combination of clinical, demographic and tumor genetics criteria, eligible patients are welcomed to an in-person consultation with an Ivy Center Navigator, who will guide them through the clinical trial process.
Explore Current Trials
Our brain tumor clinical trials are designed with the goal of discovering a breakthrough in brain cancer treatment. Explore active clinical trials currently enrolling at the Ivy Brain Tumor Center.
Complete Trial Screening Today
Each Ivy clinical trial has unique enrollment criteria. If you want to learn whether you or a loved one may be eligible, please submit a free trial screening request here or call 602-406-8605 to speak to an Ivy Navigator.
Latest from Ivy
News
An early clinical trial of 5-ALA sonodynamic therapy in recurrent high-grade glioma
Last week, the Ivy Brain Tumor Center published a manuscript in Science Translational Medicine authored by Nader Sanai, MD, Shwetal Mehta, PHD, Artak Tovmasyan, PHD, An-Chi Tien, PHD, Igor Barani, MD, Charuta Furey, MD, and Zaman Mirzadeh, MD, in collaboration with other Ivy Center team members. The manuscript presents results from our early phase clinical trial utilizing sonodynamic therapy (SDT) in recurrent high-grade glioma patients. SDT pairs 5-aminolevulinic acid (5-ALA), which is metabolized to protoporphyrin IX in glioma cells, with noninvasive, image-guided focused ultrasound to trigger tumor-selective oxidative injury.
News
Phase 3 Gliofocus Study Drug, Niraparib, Granted Orphan Drug Designation by U.S. FDA for Treatment of Malignant Glioma, including Glioblastoma
The U.S. FDA has granted ODD to niraparib for the treatment of malignant glioma, including GBM. The designation is supported…
News
CDK4/6 and mTOR inhibition in high-grade glioma
This week, the Ivy Brain Tumor Center published a manuscript in the Oxford University Press on behalf of the Society for NeuroOncology. The manuscript was authored by Nader Sanai, MD, Shwetal Mehta, PHD, and Roel G.W. Verhaak, PHD, in collaboration with other Ivy Center team members.
The manuscript illustrates the results of our Phase 0/1 clinical trial combining two targeted drugs ribociclib (CDK4/6 inhibitor) and everolimus (mTOR inhibitor) in recurrent high-grade glioma patients, aiming to identify brain-penetrant combinations and assess their impact on malignant cell states.
Blog
Park Ranger, Author Navigates Wild Terrain After Glioblastoma Diagnosis
In New Mexico, during the summer of 2023, Jeff Muse’s world changed. While serving as a park ranger and publishing his first book, he went from protecting public lands to uncharted territory when he was diagnosed with brain cancer. Jeff, 56, now in a clinical trial at the Ivy Brain Tumor Center, has found a way to navigate each day. He calls it “an equation for life.” Not a cure, not a solution, just a path—simple, hard-won, and very personal.
Blog
Father Beats Medulloblastoma, a Rare Brain Cancer in Adults
In less than two months, Joshua Zahn went from living as a healthy 31-year-old father and financial advisor to embarking on an arduous brain cancer journey. But thanks to the world-class care at Barrow Neurological Institute, combined with Joshua’s strong support system and own determination, he overcame his aggressive tumor and returned to his life.
Blog
Ivy Brain Tumor Center Hosts European investigator meeting for Gliofocus Study
Last month, leaders from the Ivy Brain Tumor Center traveled to Madrid, Spain, for the European Investigator Meeting for the Phase 3 Gliofocus Study. The meeting brought together 136 participants from 48 clinical trial sites across 13 countries to align on study goals, review protocols, and address challenges to ensure consistency and collaboration across all locations.
